Abstract: Automatic administration of drugs to control cardiovascular function during and after surgery has received considerable attention. Although the potential benefits associated with such a technology remain unquestioned, the several adaptive control strategies proposed thus far have had very limited success in practice. In developing robust adaptive control methodologies for drug dosing in cardiovascular applications, we have analysed a well-known multiple-model adaptive control strategy for blood pressure control. The results reveal that no guarantee of protection against actually inserting a destabilising controller into the closed-loop is given and one cannot even put a global upper bound on the time during which the destabilising controller is attached. We advocate caution towards issues which in the past may have been either disregarded or not subjected to a systematic analysis as instability could be fatal in the context of a clinical application.
INTRODUCTION
Haemodynamic stability is an important physiological state in which the human body's cardiovascular system is functioning correctly. Adequate blood flow is provided as cardiac output by the heart's ventricles and pressurisation of the blood vessels (mean arterial pressure-MAP) lies within an acceptable range; high enough for all vital organs to be adequately perfused and low enough not to impair the natural mass transport phenomena between the bloodstream and the tissues or cause the bursting of vessels leading to haemorrhage.
Maintaining haemodynamic stability is a task of critical importance, and several physiological control systems naturally exist within the human body to respond to external stimuli while maintaining adequate flow rates and pressures in the system. System instability can lead to severe organ damage or even death. For this very reason, patients whose physiological control systems become ineffective due to illness, trauma or surgery require close clinical attention and monitoring of their condition in order to ensure that the plant (i.e., their cardiovascular system) does not drift too far away from its physiological operating point. In some cases, clinicians may even wish to set and maintain a non-physiological operating point, for example a lower blood pressure to facilitate surgery (Furutani et al. (1995) ). From an engineering point of view, this constitutes a closed-loop feedback control problem.
This work was supported in part by the ARC Discovery-Projects Grant DP1095290. 1 Corresponding Author. firstname.surname@anu.edu.au Clinical intervention to artificially control haemodynamic variables is based on the intravenous administration of suitable drugs. Infusion rates are adjusted manually (i.e., an operator acts as the controller to close the feedback loop) and successful stabilisation of a patient relies on the skill and experience of the clinician as well as their alertness and ability to promptly identify and respond to early signs of destabilisation. Given the critical nature of this task, the creation of a safe and robust automatic control system capable of maintaining haemodynamic stability in a patient would be of great clinical interest in terms of reduced patient risk (Bailey and Haddad (2005) ). It would also have the potential to improve health outcomes and lower healthcare costs through the automation of tasks and the optimisation of drug dosing. Despite several attempts over the past two decades to find solutions to the above problem, very few have made it past the experimental stage and, to the authors' knowledge, to date, none have been commercially successful (Bequette (2007) ).
A detailed overview of the literature in the field of automatic control of blood pressure can be obtained through a number of existing review articles (Parker and Doyle (2001) ; Araki and Furutani (2005) ; Bailey and Haddad (2005); Bequette (2007) ). For the purpose of this paper, it is sufficient to highlight that a core difficulty encountered by all authors is that of substantial variability in pharmacokinetic and pharmacodynamic parameters among individuals and even within the same individual over time (Bailey and Haddad (2005) ), as well as the presence of significant, variable delays along the drug's pathway (Delapasse et al. (1994) ). These make the development of a control methodology through a worst-case-scenario approach impossible. In order for an automatic control system to satisfy stability and performance requirements in the face of variability in patients' parameters, a range of adaptive control strategies have been proposed. A popular choice has been that of Multiple-Model Adaptive Control (MMAC) (He et al. (1986) ; Martin et al. (1987) ; Yu et al. (1992) ), which assumes that a patient's response can be matched at any time with that of one of several models included in a model bank. A controller designed for the best matching model is then placed into the feedback loop, where it is expected to yield satisfactory performance.
We provide a detailed analysis of one of the aforementioned methods to expose a number of critical issues which, in the authors' view, have not received sufficient consideration. Section 2 defines the adaptive control setting drawing on the pioneer work of Martin et al. (1987) . Section 3 describes a number of computational simulations performed using the system presented in Section 2. Section 4 outlines some significant simulation results. Finally, Section 5 contains a discussion of the results and describes the future direction of this work. Martin et al. (1987) propose a multiple-model adaptive control (MMAC) strategy for automatic administration of sodium nitroprusside (SNP); a drug used to lower blood pressure in human patients. While this work is somewhat dated, we note that it remains a significant contribution, as a number of supervisory methods later developed on the basis of the original MMAC architecture (see Martin et al. (1992b,a) ) were utilised in the IVAC Titrator (IVAC Corporation, San Diego, CA), the only ever commercialised device-albeit unsuccessful-for automatic closed-loop delivery of SNP.
PROBLEM AND MODEL DESCRIPTION
The adaptive control approach of Martin et al. (1987) is based on the simplified model of a human patient shown in Fig. 1 . The patient is modelled as a plant containing three first-order linear-time-invariant (LTI) subsystems describing drug diffusion and recirculation, as well as a pure time delay component. All parameters of the system are considered fixed with the exception of the plant gain K and time delay constant T. The system P : u → y receives a drug dose at the input u and produces a pressure drop at the output y. The overall transfer function of the patient system is given by τ 1 = 50s, τ 2 = 30s, τ 3 = 10s are the time constants of the firstorder LTI subsystems; α = 0.5 is the recirculation constant; K is the patient gain. The patient's Mean Arterial Pressure (MAP) y 1 is determined by the affine relationship
where p 0 is the patient's natural value of MAP when no SNP is administered.
The control performance specifications are:
• to achieve a rise time (10% to 90% of the setpoint value) of 10 minutes or less; • to limit overshoot to less than 10 mmHg;
• to avoid administration of a toxic dose of SNP, defined as one in excess of 600 µg/(kg·h).
The MMAC architecture is shown in Fig. 2 . In the closedloop system, the pressure output y of the plant (patient) is compared with that of a bank of seven models designed using the system in (1). See Table 1 for a list of gain values used. On the basis of the difference (residuals) between the patient output and the model bank outputs, an iterative computation of weights is carried out. Weights are assigned to the controllers in the controller bank so that the controller corresponding to the model which is most representative of the plant receives the largest weight (for details on the weight computation process, refer to Martin et al. (1987) ). The control signal u is given by the weighted average of the controller bank outputs. A delay detection algorithm also re-evaluates the value of the delay constant T after every setpoint change. The effect of delay is compensated by utilising a bank of seven Smith predictors (one per each model in the model bank) having the following transfer function
where K i is the value of K for the i th model in the model bank as in (1) and T * is the best available estimate of the plant delay. A noise component at the system output (gaussian noise, mean 0 mmHg, standard deviation 2 mmHg) is also part of the simulation set-up, reproducing the measurement error of an arterial pressure port.
The seven controllers in the controller bank were designed following the specifications provided in the original paper of Martin et al. (1987) , namely a PI controller structure which would achieve a rise time (10% to 90% of the setpoint value) of 2 minutes or less and no more than 10% overshoot when used in closed-loop with the corresponding plant model. The controller bank equations used for the simulations presented in this paper are expressed by 
The closed-loop step response of a controller-model combination can be seen in Fig. 3 , where it is shown that the response fits the required specifications.
Finally, the control system includes three nonlinear blocks marked as F 1 , F 2 and F 3 in Fig. 2 . These act as additional safety measures for the system. Block F 1 limits the maximum infusion rate to a value lower than the toxicity threshold for SNP. Block F 2 protects the patient by impeding infusion of SNP if pressure is below a minimum safe value. Block F 3 only allows a positive control signal u to be fed to the plant (this is required as it is impossible to administer a negative drug dose). Martin et al. (1987) (also Martin et al. (1992a) ) report that this MMAC system performed well in a variety of operating conditions. The next section presents three computer simulations which were performed in an attempt to expose potential instances of system instability.
ANALYSIS AND COMPUTER SIMULATIONS
A fundamental requirement of MMAC is that the true plant can be identified by matching it at any point in time with one of a number of candidate models. As the true plant is, to some extent, unknown, a risk exists that discrepancies between the true plant and the models (plant-model mismatch) could affect system performance. Unmodelled dynamics may become significant when the plant is connected to a certain controller in a closed-loop configuration. The identification procedure may even fail to the extent that a destabilising controller is switched in. This highlights the key role of the supervisory (switching) algorithm in MMAC in readily detecting instability and preventing undesirable values in the transient response.
These critical issues are analysed in the following three simulations (which will be referred to as "experiments").
Plant-model mismatch
The original MMAC system of Martin et al. (1987) assumes that a number of plant parameters can be consid- ered constant and the plant delay can be determined accurately. Our first experiment aimed to ascertain whether introducing significant (although not unrealistic) mismatch between the true plant and the models used in the system could lead to system instability.
We assumed that the system of Section 2 was set up to control a patient (baseline MAP=90 mmHg) throughout a long operation (duration of simulation: 22,200 s, i.e., 6 hrs 10 min), and that at the beginning of the procedure good matching existed between the true plant (the patient) and the plant models used in both the Smith predictors and the model bank (patient K=10 mmHg/(ml/h); delay parameter T = T * =18 s). The target MAP was set at 80 mmHg (a 10 mmHg drop from baseline) and maintained constant throughout the procedure. After an initial 10-minute settling period, a number of changes to the plant were set to occur over three distinct two-hour time blocks as follows (see also Fig. 4 ):
• During the first time block (0-2 hrs), the patient's gain parameter K was set to fluctuate between a value of 10 mmHg/(ml/h) and 2.5 mmHg/(ml/h) according to a sinusoidal pattern. Such a range was chosen because it requires several models/controllers to be switched in and out in order for the setpoint to be maintained and would therefore facilitate observation of the system's switching behaviour. In clinical terms, a shift in the gain parameter corresponds to a change in the patient's sensitivity to the drug which is being administered.
• During the second time block (2-4 hrs), the sinusoidal gain change continued and a slow drift in the patient delay was introduced. The plant delay was increased from T =18 s to T =70 s according to a ramp function. In clinical terms, such an increase may correspond to slower transport phenomena (e.g., due to cardiovascular and/or metabolic reasons) along the drug's pathway. As there is no setpoint change, the delay value used in the MMAC models and Smith predictors is not reassessed and remains at T * =18 s.
• During the last time block (4-6 hrs), the gain change pattern continued and the delay mismatch was maintained fixed at the maximum value. An increase in the recirculation constant α (see Fig.1 ) from 0.5 to 0.75 was also introduced, again following a ramp function. From a pharmacokinetics point of view, this roughly corresponds to an increasingly slower removal of SNP from the blood pool.
Closed-loop instability with a stable controller
The second experiment was concerned with the presence of a destabilising controller within the controller bank. Such a controller could arise as a result of a fault, a design error or significant model mismatch. The aim was to analyse whether the MMAC system would prevent a destabilising controller from being switched into the loop and, in the event that the destabilising controller were switched in, whether the system would recognise instability and switch to a different controller without leading to dangerous pressure values.
This experiment also involved a target pressure of 80 mmHg, this time over a shorter control horizon of 12000 Fig. 3 . Closed-loop pressure response of the combination of controller C 3 and model P 3 to a step reference MAP drop of 10 mmHg (90 to 80 mmHg).
Step change occurring at 80s (marked). All combinations of plant model P i and corresponding controller C i exhibit a similar closed-loop response.
s (3 hrs 20 min). After 10 minutes of initial settling time, the patient's gain parameter K was set to change between 0.25 mmHg/(ml/h) and 2 mmHg/(ml/h) according to a sinusoidal pattern. The range was chosen as it would allow for the switching of four different controllers. Controller C 3 (corresponding to the gain range 0.89 to 1.65 mmHg/(ml/h)) was changed to
This controller is destabilising even when the delay is perfectly compensated by the Smith predictor.
Closed-loop instability with an unstable controller
A third experiment, similar to the previous one, was designed to study the effect of an unstable controller. In the same simulation of Section 3.2, controller C 3 was restored to its original transfer function, while controller C 7 was changed to
This is an oscillating unstable controller. It is important to point out that controller C 7 should not be allowed to switch in, as it caters for a gain range which is much higher than the patient gain used in the simulation. The aim of this simulation was to evaluate whether such a wildly oscillating component could affect system performance, e.g., by forcing accidental controller switchings. Again, to draw a parallel with a practical situation, such an undesirable controller could be the result of a fault.
RESULTS AND THEIR INTERPRETATION
In all simulations, the data for output pressure y 1 and model weights were collected. In this section, all observed instances of instability are presented and their likely causes are analysed.
The results for the plant-model mismatch experiment are shown in Fig. 4 , where each two-hour block is highlighted using dotted lines. During the first (0-2 hrs) and second (2-4 hrs) time block, the MMAC system was able to maintain stability despite the varying plant gain and the increasing delay mismatch. During the final two hours of the simulated procedure (4-6 hrs), however, the additional presence of mismatch in the plant parameter α led to an incorrect weight assignment pattern and unsuitably large output pressure fluctuations. It should be pointed out that because of the three nonlinear limitations imposed (i.e., a strictly positive control signal, an upper limit on infusion rate and a low-pressure infusion cut-off) the system output cannot diverge towards infinitely large values. For the purpose of the clinical application, however, a wildly oscillating behaviour such as that observed in the final part of this simulation not only fails to meet the specifications but would also be incompatible with life and therefore amounts to system instability.
A closer analysis of the plant model (Fig. 1) shows that the increase in the recirculation constant α causes the plant's steady state gain to double (calculations not shown due to space limitation). This means that at the higher range of the oscillation of parameter K, a suitable model for the plant does not exist in the model bank. This contributes to model P 7 being repeatedly incorrectly identified as the best fitting model, as observed during the last two-hour block. As a result, a large weight is assigned to an unsuitable (overly aggressive) controller and this, combined with significant delay mismatch, forces the closed-loop system into instability.
The presence of a destabilising controller with a stable transfer function leads to instances of instability in the second experiment As shown in Fig. 5 , every time the drifting plant gain enters the range associated with C 3 , the destabilising controller of equation (5) is engaged (by assignment of a large weight), causing the output pressure to either oscillate or deviate from the target setpoint to an unacceptable extent. The destabilising controller is only phased out when the plant gain leaves the critical region; this generates the alternating stable-oscillating pattern seen in Fig. 5 . This type of behaviour could be expected of this MMAC system, where controllers are switched in (or better, weighted in) according to the residual between the output of the plant and that of one of seven possible plant models. The matching between the plant and the model may be computed as accurate even when a destabilising controller is switched in, causing the system output to consistently diverge.
The third experiment, featuring a destabilising controller with an unstable transfer function, shows yet another example of instability. As expected, controller C 7 of equation (6) is never assigned a large weight. Despite this, the system becomes grossly unstable. This finding, which may appear counter-intuitive at first, is the result of an intrinsic issue which exists within this system. The iterative weight assignment algorithm requires that all candidate models (and their respective controllers) be assigned a nonzero weight. The weight function has a small nonzero minimum which is assigned to models unrepresentative of the plant (0.1% in this simulation). As the output of the unstable controller tends to grow unboundedly, its contribution to the control signal, determined as a weighted sum of the outputs of all candidate controllers, may become signifi- cant after some time no matter how small the weight factor is. This is exactly what can be seen in Fig.6 , where until approximately t=90 min the system is stable, but then commences to drift and finally bursts into oscillations. Close observations of the overall controller signal (not shown) confirms that instability occurs when the contribution of controller C 7 after weighting dominates over the other addends in the weighted sum.
DISCUSSIONS AND FUTURE WORK
The MMAC system for automatic regulation of blood pressure proposed by Martin et al. (1987) was tested in the three experiments of Section 3 and instances of instability were observed. The cases presented are simple yet purposely created to exploit potential weaknesses of the original approach. Nonetheless, an attempt has been made to refer any changes made back to realistic circumstances. The key issues which have been drawn upon-i.e., those of plant-model mismatch and the presence of destabilising controllers-are generic problems affecting unsafe adaptive control systems.
As a result of a parameter change, significant plant-model mismatch was generated, to the point that accurate plant identification could not take place with the available model bank. This, combined with a reduction in phase margin caused by a substantial amount of uncompensated plant delay, ultimately forced the system into a condition where no stabilising controller existed. This raises the general question of how large a bank of candidate models (and associated controllers) is required in order to ensure robust stability. The problems here are three-fold. Firstly, there is a need to ensure that a broad range of operating conditions of the system are included in the controller design process, and this may be achieved by more accurate modelling of pharmacokinetics, pharmacodynamics and the human cardiovascular system, as has been proposed by several authors (Martin et al. (1986) ; Yu et al. (1990) ; Woodruff et al. (1997) ; Parker and Doyle (2001) ). Secondly, however, as the clinical application generally requires that MAP be maintained at a steady level, a lack of persistent model excitation may degrade the ability to accurately match the true plant with one of many candidate models. Further, as discussed in Anderson and Dehghani (2008) , on-line identification of a plant is a closed-loop identification problem and the controller connected to the plant affects the outcome of the identification process. Transfer functions performing similarly in open loop may perform differently in closed-loop.
The system of Martin et al. (1987) performed inadequately in the presence of a destabilising controller. While for the purpose of creating an example a destabilising controller was deliberately added to the controller bank, in a real, more complex system a destabilising plant-controller combination may arise as a consequence of model mismatch. A controller which is able to stabilise a certain plant parameter set may cease to do so when the parameters change. In a safe system, a destabilising controller should not be switched in, or at least switched out soon enough not to allow the system states to reach unsuitable values (Anderson and Dehghani (2008) ). The results from the simulations show that not only a destabilising controller could be assigned the largest weight, but that it is not even possible to place a global upper bound on the time during which the destabilising controller is attached, as the weight assignment algorithm is based solely on the transfer functions of the plant and plant models and does not include any information about the controller. Further, the third experiment shows that the weighted averaging of all controllers does not exclude a priori possible interferences on the control signal even by controllers which should remain disengaged.
The MMAC architecture used in this paper underwent some modifications (see Martin et al. (1992b) ) with the introduction of an improved supervisory algorithm, mainly to enhance output disturbance rejection. It is possible that these improvements would reduce the likelihood of some of the instability events presented here (e.g., large MAP fluctuations may be reduced by limiting the rate of change of infusion). However, to the best of the authors' knowledge, while the supervisory algorithms may be a successful ad-hoc solution to practical problems encountered during clinical implementation, intrinsic adaptive control issues such as those identified in this paper have not been subjected to a systematic analysis.
The principal reason for seeking the development of automatic drug delivery is the improved accuracy in administration which would result, reducing the risk of underor overdosing. On the other hand, however, the creation of a closed-loop control system which excludes the human operator (clinician) introduces risk of a different natureespecially when the loop is designed to control a vital organ or system-a type of risk which regulatory authorities hold in great consideration (Bequette (2007) ) and possi- (Bequette (2007) ), although these issues alone would arguably not stand in the way of a truly successful device. In the authors' view, while various practical solutions for the problem of automatic drug delivery have already been proposed, the resolution of a number of outstanding robust stability issues in adaptive control systems may be the missing step in the development of safer and more broadly accepted solutions.
This paper is the first step in a comprehensive research effort to analyse the work which has been done in the area of automatic dosing of vasoactive drugs. Future work will revisit the most effective existing solutions in light of recent advancements in robust adaptive control theory.
